Do analysts prefer PYRGF or MTVA?

MetaVia has a consensus price target of $20.00, indicating a potential upside of 1,251.35%. Given MetaVia's stronger consensus rating and higher probable upside, analysts plainly believe MetaVia is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MetaVia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is LSTA or MTVA more profitable?

Lisata Therapeutics' return on equity of -103.54% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -103.54% -83.08% MetaVia N/A -172.92% -89.39%

Does the media favor LSTA or MTVA?

In the previous week, Lisata Therapeutics and Lisata Therapeutics both had 1 articles in the media. MetaVia's average media sentiment score of 1.89 beat Lisata Therapeutics' score of 0.94 indicating that MetaVia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lisata Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MetaVia 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is MTVA or DARE more profitable?

Dare Bioscience's return on equity of 0.00% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -172.92% -89.39% Dare Bioscience N/A N/A -46.22%

Does the media prefer MTVA or DARE?

In the previous week, MetaVia and MetaVia both had 1 articles in the media. MetaVia's average media sentiment score of 1.89 beat Dare Bioscience's score of 0.62 indicating that MetaVia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MTVA or ATNM more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -172.92% -89.39% Actinium Pharmaceuticals N/A -100.85% -47.89%

Does the media refer more to MTVA or ATNM?

In the previous week, MetaVia and MetaVia both had 1 articles in the media. MetaVia's average media sentiment score of 1.89 beat Actinium Pharmaceuticals' score of 0.00 indicating that MetaVia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Actinium Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MTVA or NNVC?

MetaVia currently has a consensus target price of $20.00, indicating a potential upside of 1,251.35%. Given MetaVia's higher probable upside, analysts plainly believe MetaVia is more favorable than NanoViricides. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has preferable valuation & earnings, MTVA or NNVC?

NanoViricides is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MetaVia N/A N/A -$12.97M -$5.19 N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is MTVA or NNVC more profitable?

NanoViricides' return on equity of -87.90% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -172.92% -89.39% NanoViricides N/A -87.90% -78.69%

Does the media prefer MTVA or NNVC?

In the previous week, MetaVia and MetaVia both had 1 articles in the media. MetaVia's average media sentiment score of 1.89 beat NanoViricides' score of 0.25 indicating that MetaVia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive NanoViricides 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MetaVia (MTVA) Competitors

$1.48 +0.03 (+2.07%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.44 -0.04 (-3.04%)

As of 07/2/2026 07:53 PM Eastern

Compare

MTVA vs. PYRGF, LSTA, DARE, ATNM, and NNVC

Should you buy MetaVia stock or one of its competitors? MarketBeat compares MetaVia with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MetaVia include PyroGenesis Canada (PYRGF), Lisata Therapeutics (LSTA), Dare Bioscience (DARE), Actinium Pharmaceuticals (ATNM), and NanoViricides (NNVC). These companies are all part of the "pharmaceutical products" industry.

How does MetaVia compare to PyroGenesis Canada?

PyroGenesis Canada (NASDAQ:PYRGF) and MetaVia (NASDAQ:MTVA) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

MetaVia has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
MetaVia	N/A	-172.92%	-89.39%

In the previous week, MetaVia had 1 more articles in the media than PyroGenesis Canada. MarketBeat recorded 1 mentions for MetaVia and 0 mentions for PyroGenesis Canada. MetaVia's average media sentiment score of 1.89 beat PyroGenesis Canada's score of 0.00 indicating that MetaVia is being referred to more favorably in the news media.

Company	Overall Sentiment
PyroGenesis Canada	Neutral
MetaVia	Very Positive

0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 1.4% of MetaVia shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by company insiders. Comparatively, 0.6% of MetaVia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MetaVia has a consensus price target of $20.00, indicating a potential upside of 1,251.35%. Given MetaVia's stronger consensus rating and higher probable upside, analysts plainly believe MetaVia is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

PyroGenesis Canada has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, MetaVia has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

MetaVia has lower revenue, but higher earnings than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	3.56	-$21.12M	-$0.04	N/A
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A

Summary

MetaVia beats PyroGenesis Canada on 10 of the 15 factors compared between the two stocks.

How does MetaVia compare to Lisata Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and MetaVia (NASDAQ:MTVA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 1.4% of MetaVia shares are held by institutional investors. 9.6% of Lisata Therapeutics shares are held by insiders. Comparatively, 0.6% of MetaVia shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lisata Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, MetaVia has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

MetaVia has lower revenue, but higher earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	178.45	-$16.59M	-$1.86	N/A
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A

Lisata Therapeutics' return on equity of -103.54% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
MetaVia	N/A	-172.92%	-89.39%

In the previous week, Lisata Therapeutics and Lisata Therapeutics both had 1 articles in the media. MetaVia's average media sentiment score of 1.89 beat Lisata Therapeutics' score of 0.94 indicating that MetaVia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lisata Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MetaVia	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Lisata Therapeutics currently has a consensus target price of $15.00, suggesting a potential upside of 350.45%. MetaVia has a consensus target price of $20.00, suggesting a potential upside of 1,251.35%. Given MetaVia's stronger consensus rating and higher possible upside, analysts clearly believe MetaVia is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

MetaVia beats Lisata Therapeutics on 7 of the 13 factors compared between the two stocks.

How does MetaVia compare to Dare Bioscience?

MetaVia (NASDAQ:MTVA) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

1.4% of MetaVia shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 0.6% of MetaVia shares are owned by company insiders. Comparatively, 4.1% of Dare Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dare Bioscience's return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-172.92%	-89.39%
Dare Bioscience	N/A	N/A	-46.22%

MetaVia presently has a consensus price target of $20.00, indicating a potential upside of 1,251.35%. Dare Bioscience has a consensus price target of $10.00, indicating a potential upside of 378.47%. Given MetaVia's higher possible upside, research analysts clearly believe MetaVia is more favorable than Dare Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, MetaVia and MetaVia both had 1 articles in the media. MetaVia's average media sentiment score of 1.89 beat Dare Bioscience's score of 0.62 indicating that MetaVia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MetaVia	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MetaVia has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

MetaVia has higher earnings, but lower revenue than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A
Dare Bioscience	$1.03M	30.40	-$13.40M	-$0.95	N/A

Summary

Dare Bioscience beats MetaVia on 9 of the 13 factors compared between the two stocks.

How does MetaVia compare to Actinium Pharmaceuticals?

MetaVia (NASDAQ:MTVA) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

MetaVia currently has a consensus price target of $20.00, indicating a potential upside of 1,251.35%. Actinium Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 409.68%. Given MetaVia's higher possible upside, equities research analysts plainly believe MetaVia is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Actinium Pharmaceuticals' return on equity of -100.85% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-172.92%	-89.39%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

In the previous week, MetaVia and MetaVia both had 1 articles in the media. MetaVia's average media sentiment score of 1.89 beat Actinium Pharmaceuticals' score of 0.00 indicating that MetaVia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MetaVia	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MetaVia has higher earnings, but lower revenue than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A
Actinium Pharmaceuticals	$90K	341.99	-$48.82M	-$0.75	N/A

1.4% of MetaVia shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 0.6% of MetaVia shares are held by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MetaVia has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market.

Summary

Actinium Pharmaceuticals beats MetaVia on 6 of the 11 factors compared between the two stocks.

How does MetaVia compare to NanoViricides?

MetaVia (NASDAQ:MTVA) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

NanoViricides is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

NanoViricides' return on equity of -87.90% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-172.92%	-89.39%
NanoViricides	N/A	-87.90%	-78.69%

MetaVia has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

1.4% of MetaVia shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 0.6% of MetaVia shares are held by company insiders. Comparatively, 3.6% of NanoViricides shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, MetaVia and MetaVia both had 1 articles in the media. MetaVia's average media sentiment score of 1.89 beat NanoViricides' score of 0.25 indicating that MetaVia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MetaVia	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
NanoViricides	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MetaVia currently has a consensus target price of $20.00, indicating a potential upside of 1,251.35%. Given MetaVia's higher probable upside, analysts plainly believe MetaVia is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

NanoViricides beats MetaVia on 8 of the 11 factors compared between the two stocks.

Get MetaVia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MTVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MTVA vs. The Competition

Export

Metric	MetaVia	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.49M	$3.65B	$6.82B	$12.56B
Dividend Yield	N/A	2.22%	2.68%	6.63%
P/E Ratio	-0.29	21.43	27.91	24.67
Price / Sales	N/A	324.18	532.83	96.34
Price / Cash	N/A	143.20	48.59	58.15
Price / Book	0.64	8.66	10.89	6.45
Net Income	-$12.97M	$23.81M	$3.57B	$336.71M
7 Day Performance	3.50%	3.47%	2.24%	1.37%
1 Month Performance	-44.78%	8.53%	4.60%	1.67%
1 Year Performance	-79.23%	62.64%	33.47%	24.05%

MetaVia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MTVA MetaVia	2.45 of 5 stars	$1.48 +2.1%	$20.00 +1,251.4%	-79.7%	$7.49M	N/A	N/A	8	News Coverage Positive News
PYRGF PyroGenesis Canada	N/A	$0.14 -3.4%	N/A	-56.6%	$31.59M	$9.14M	N/A	90
LSTA Lisata Therapeutics	2.7779 of 5 stars	$3.37 -2.2%	$15.00 +345.6%	+22.0%	$30.66M	$170K	N/A	30
DARE Dare Bioscience	3.2154 of 5 stars	$2.02 -2.9%	$10.00 +395.0%	-12.9%	$30.26M	$1.03M	N/A	30
ATNM Actinium Pharmaceuticals	1.9711 of 5 stars	$0.96 -4.9%	$5.00 +420.3%	-31.4%	$30.15M	$90K	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MTVA) was last updated on 7/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MetaVia (MTVA) Competitors

MTVA vs. PYRGF, LSTA, DARE, ATNM, and NNVC

How does MetaVia compare to PyroGenesis Canada?

Summary

How does MetaVia compare to Lisata Therapeutics?

Summary

How does MetaVia compare to Dare Bioscience?

Summary

How does MetaVia compare to Actinium Pharmaceuticals?

Summary

How does MetaVia compare to NanoViricides?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTVA vs. The Competition

MetaVia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MetaVia (MTVA) Competitors

MTVA vs. PYRGF, LSTA, DARE, ATNM, and NNVC

How does MetaVia compare to PyroGenesis Canada?

Is PYRGF or MTVA more profitable?

Does the media favor PYRGF or MTVA?

Do insiders and institutionals believe in PYRGF or MTVA?

Do analysts prefer PYRGF or MTVA?

Which has more volatility & risk, PYRGF or MTVA?

Which has stronger valuation and earnings, PYRGF or MTVA?

Summary

How does MetaVia compare to Lisata Therapeutics?

Do insiders and institutionals have more ownership in LSTA or MTVA?

Which has more volatility and risk, LSTA or MTVA?

Which has better earnings and valuation, LSTA or MTVA?

Is LSTA or MTVA more profitable?

Does the media favor LSTA or MTVA?

Do analysts recommend LSTA or MTVA?

Summary

How does MetaVia compare to Dare Bioscience?

Do institutionals & insiders have more ownership in MTVA or DARE?

Is MTVA or DARE more profitable?

Do analysts rate MTVA or DARE?

Does the media prefer MTVA or DARE?

Which has more volatility and risk, MTVA or DARE?

Which has higher valuation & earnings, MTVA or DARE?

Summary

How does MetaVia compare to Actinium Pharmaceuticals?

Do analysts rate MTVA or ATNM?

Is MTVA or ATNM more profitable?

Does the media refer more to MTVA or ATNM?

Which has better valuation & earnings, MTVA or ATNM?

Do institutionals and insiders believe in MTVA or ATNM?

Which has more risk & volatility, MTVA or ATNM?

Summary

How does MetaVia compare to NanoViricides?

Which has preferable valuation & earnings, MTVA or NNVC?

Is MTVA or NNVC more profitable?

Which has more volatility and risk, MTVA or NNVC?

Do institutionals & insiders have more ownership in MTVA or NNVC?

Does the media prefer MTVA or NNVC?

Do analysts prefer MTVA or NNVC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTVA vs. The Competition

MetaVia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools